Monover (Ferric Derisomaltose)

Ferric derisomaltose is an iron‑carbohydrate complex that, after IV infusion, is captured by the reticulo‑endothelial system. Inside macrophages the complex releases elemental iron, which binds to transferrin and becomes available for hemoglobin synthesis and other iron‑dependent processes, thereby correcting the deficiency.

The prescribing physician determines the dose based on the individual’s iron deficit, body weight, and clinical condition. Dosing is individualized, may be given as a single infusion or divided over several sessions, and is administered under medical supervision in a controlled setting.

Safety data for ferric derisomaltose in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Monover, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Monover (ferric derisomaltose) delivers a larger amount of elemental iron per infusion compared with iron sucrose, allowing for fewer administrations. Compared with ferric carboxymaltose, it has a similar safety profile but differs in carbohydrate ligand, which may influence tolerability in some patients.

Monover should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, inspect the solution for particulate matter and ensure the container is intact.

Monover is administered as an intravenous infusion by a qualified healthcare professional. The infusion rate is controlled according to the prescribed dose, and patients are monitored during and after the infusion for any signs of adverse reactions or hemodynamic changes.

Serious risks include anaphylactic or severe hypersensitivity reactions, acute hemolysis, and marked hypophosphatemia. Prompt recognition of symptoms such as difficulty breathing, rash, sudden drop in blood pressure, or severe muscle weakness is essential, and immediate medical intervention should be initiated.

Monover is contraindicated in patients with known hypersensitivity to ferric derisomaltose or any of its excipients. It should also be avoided in individuals with active severe infections, uncontrolled hypertension, or those who have experienced previous severe reactions to intravenous iron preparations.